Glaxo's antiviral ills not deemed contagious

Article Abstract:

London, England-based Glaxo Wellcome and Melbourne, Australia-based Biota Holdlings failed to gain approval from the Food and Drug Administration (FDA) for their influenza treatment preparation zanamivir (Relenza). Relenza was the first neuraminidase inhibitor to reach an FDA committee. The decision against approval may herald regulatory problems for similar drugs. Competing companies are reticent about offering comments, however industry sources are minimizing the committee's rejection and blaming design flaws in the North American phase III trial instead of the design of the drug itself.

Government regulation (cont), Pharmaceutical Preparation Manufacturing, Antiviral Respiratory Preps, Glaxo Wellcome PLC, Antiviral agents, Respiratory system agents, Biota Holdings Ltd.

---

Making prevention pay

Article Abstract:

The threat of biological weapons and the easy availability of funding for biodefense from the United States government have resulted in an increase in the research and development of many new vaccine and anti-infective programs at many biotech companies. The development of new technologies may help in reinvigorating vaccine research but it is difficult to reduce the gap between the discovery of the disease and the production of an effective vaccine.

Government expenditures, General services, Science & research, Drugs, Research, Safety and security measures, Biotechnology industry, Biotechnology industries, Vaccines, Bioterrorism, Government finance

---

Similar abstracts:

• Abstracts: GAAP, evaluation and decision-making. Improving on GAAP. The world according to US GAAP
• Abstracts: Man management? Women and the use of debt to control personal relationships. Understanding consumption: contributions from a narrative perspective
• Abstracts: TimesSquare Capital Management, Inc. King Investment Advisors, Inc
• Abstracts: Airline companies. The airline industry. Airline stocks
• Abstracts: US expands anti-bioterrist measures. US, EU prepare for further biotech food dispute. EU-US experts urge stiffer rules for biotech foods

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.